Research programme: sorbitol dehydrogenase inhibitors - Pfizer
Latest Information Update: 05 Sep 2006
At a glance
- Originator Pfizer
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Diabetic complications in USA (unspecified route)
- 16 Apr 2003 Preclinical trials in Diabetic complications in USA (unspecified route)